HDTenEightyP/NetNews huggingface dataset:
From: jschwarz@lonestar.utsa.edu (Jan A. Schwarz)
Newsgroups: sci.med
Subject: Hurting Ribs (during pregnancy)
Date: 1 Oct 92 14:07:12 GMT
Organization: University of Texas at San Antonio


   My daughter is experiencing a pain on the left side of her
   abdomen.  She said it feels like her ribs are bruised.  She is
   six months pregnant.  The pain gets more intense as the day goes
   on, especially after she has eaten.  She said it hurts inside but
   also feels very tender to the touch.  In the mornings when she first
   gets up it doesn't hurt.  But by lunch, when she eats, it starts
   hurting.

   Any suggestions will be greatly appreciated.

   Jan
From: dyer@spdcc.com (Steve Dyer)
Newsgroups: sci.med
Subject: Re: Antidepressant Drugs:  Zoloft?
Date: 6 Oct 92 03:44:31 GMT
Article-I.D.: spdcc.1992Oct6.034431.12722
Organization: S.P. Dyer Computer Consulting, Cambridge MA

In article <1992Oct6.022646.16768@dartvax.dartmouth.edu> Daniel.Jack.Blumenfeld@dartmouth.edu (Daniel Jack Blumenfeld) writes:
>I'm looking for clinical-trial information on the new antidepressant drug
>Zoloft (sp?).  I am not sure what phamaceutical company developed the
>drug, and whether it is still in the clinical trial stage or has recently
>been approved by the FDA... it's not in the 1992 PDR.  Medical journal
>references would be helpful (I've already searched MEDLINE without any
>success).

It's been FDA approved for a little less than a year.  It's a serotonin
reuptake inhibitor similar in action to fluoxetine (Prozac).  There are
certainly references on it to be found in MEDLINE: do a search under its
non-proprietary name sertraline.  I think that Pfizer is the manufacturer,
though I might be wrong about that last tidbit.

-- 
Steve Dyer
dyer@ursa-major.spdcc.com aka {ima,harvard,rayssd,linus,m2c}!spdcc!dyer
Newsgroups: sci.med.aids
From: <MADLANSACAY%FORDMULC.BITNET@VM.USC.EDU>
Subject:  Looking for info
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6284
Organization: unspecified
Date:     Tue,  6 Oct 1992 10:46 EST

Hello.

Does any have info on the VA Study on passive
immunotheraphy done about two years ago?  I need
the basic info like the actual name of study, PI,
study design and results of the study.  If anyone
can direct me to where I can find any of the information
I need, I appreciate it alot.

Noel
Newsgroups: sci.med.aids
From: "Paul M. Karagianis" <KARYPM%SJUVM.BITNET@VM.USC.EDU>
Subject:      US Population
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6269
Organization: unspecified
Date:         Fri, 02 Oct 92 20:46:13 EDT

Given the high information rate of this group allow me a quick
handwave here to point out that the 350,000,000 figure being
kicked around here lately as the US population is off by about
100,000,000.  The January 1989 census estimate was about 247M
and my SWAG for the current total would be around 255 million.

I like using 250 M for sanity checks since it lets me convert
$1 Billion (1E9) into $4 per capita.  FYI I round 130 M employed
down to 100 M middle income to convert $1B to $10 out of my pocket.
                                           -Kary
Newsgroups: sci.med.aids
From: jfh@netcom.com (Jack Hamilton)
Subject: Project Open Hand changes criteria
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6252
Organization: Netcom - Online Communication Services  (408 241-9760 guest) 
Date: Wed, 30 Sep 1992 15:38:22 GMT

The San Francisco group Project Open Hand, which provides free groceries
and hot meals to people with AIDS, has relaxed its eligibility rules.  

The previous criteria where a diagnosis or AIDS or disabling illness caused
by HIV infection, and a monthly income under &50.  

The new criteria require only HIV infection and illness.  The income
requirement has been dropped.  

I don't know whether this will set a trend - they may get more business
than they can handle under the new criteria. 

-- 

-----------------------------------------------------------------------
Jack Hamilton   jfh@netcom.com   P. O. Box 281107   SF, CA   94128-1107
From: bigoldberg@igc.apc.org (Billi Goldberg)
Newsgroups: sci.med.aids
Subject: Low-dose AZT
Date: 3 Oct 92 16:15:49 GMT
Organization: unspecified
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6271

Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA;
Pettinelli CB; Davies G; Richman DD; Leedom JM.
                         
A pilot study of low-dose zidovudine in human immunodeficiency virus
infection [see comments].       
                                       
New England Journal of Medicine, 1990 Oct 11, 323(15):1015-21.             

Abstract: 

BACKGROUND. Zidovudine delays the progression of human
immunodeficiency virus (HIV) infection but is associated with 
hematologic toxicity at high doses. Regimens are needed that preserve or 
enhance efficacy and reduce toxicity. Acyclovir has been reported to 
potentiate the effect of zidovudine on HIV in vitro. 

METHODS. We conducted a Phase II open-label, dose-escalating trial to 
evaluate the clinical and antiviral effects of zidovudine at low (300 mg 
daily, 28 subjects), medium (600 mg, 24 subjects), and high (1500 mg, 15 
subjects) doses, either with or without acyclovir (4.8 g) by random 
assignment. The subjects had the acquired immunodeficiency syndrome 
(AIDS)-related complex, but not AIDS. All of them had either HIV p24 
antigenemia or plasma viremia and CD4-lymphocyte counts of 200 to 500 
per cubic millimeter when they began treatment. 

RESULTS. Performance scores and fatigue improved the most in the low- 
and  medium-dose zidovudine groups (both P less than or equal to 0.025). 
Those assigned to low-dose zidovudine gained the most weight and had the 
greatest improvement in the mean CD4-lymphocyte count (from 321 per 
cubic millimeter at base line to 412 per cubic millimeter after 12 
weeks, P = 0.01). The proportion of subjects in whom HIV antigenemia 
resolved, the decrease in the level of antigenemia, and the reduction in 
the plasma virus titers were similar at all three doses. Subjects 
assigned to receive the low or medium dose who subsequently crossed over 
to the 1500-mg dose (n = 19) did not have an increase in CD4-cell counts 
or a decline in levels of HIV antigen, but they did have dose-related 
toxicity. The addition of acyclovir to zidovudine was well tolerated, 
but it did not enhance any of zidovudine's antiretroviral effects. 

CONCLUSIONS. In this pilot study a very low dose of zidovudine (300 mg) 
had clinical and virologic effects similar to those of higher daily 
doses (600 and 1500 mg). The minimal effective dose of zidovudine for 
the treatment of HIV infection has yet to be determined, and further 
studies of very low daily doses are warranted.
Newsgroups: sci.med.aids
From: dyer@spdcc.com (Steve Dyer)
Subject: Re: CDC Summary 10/5/92
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6280
Organization: S.P. Dyer Computer Consulting, Cambridge MA
Date: Mon, 5 Oct 1992 17:55:18 GMT

In article <1992Oct5.162140.24210@cs.ucla.edu> bigoldberg@igc.apc.org (Billi Goldberg) writes:
> "Feasibility of AIDS Vaccine in Doubt" Chemical and Engineering News 
>(09/21/92) Vol. 70, No. 38, P. 17
>     Attempts to develop a vaccine against HIV are destined for  
>failure, according to Albert B. Sabin, the now-retired  microbiologist, 
>who developed the oral polio vaccine.

Whatever the merits of Sabin's arguments are or aren't (and I honestly
haven't digested that article for content), it should be remembered that
he and Jonas Salk (of the original inactivated injected polio vaccine,
and now engaged in HIV vaccine research) are mortal enemies in both the
profesional and personal spheres.  There's no love lost between them,
so implicits criticism on Salk's efforts should be read with this in
mind.  He might well be leaving some points out which would otherwise
weaken his argument.  Gaining points in the press has always been one of
their tactics in their personal war.

-- 
Steve Dyer
dyer@ursa-major.spdcc.com aka {ima,harvard,rayssd,linus,m2c}!spdcc!dyer
From: downey%homer.CS.Berkeley.EDU@ucbvax.Berkeley.EDU (Allen B. Downey)
Subject: Re: KS and Immunosuppression
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6238
Organization: University of California, Berkeley
Date: 28 Sep 1992 17:54:37 GMT

>Page 243:"At least 49 cases of Kaposi's sarcoma occurring in patient's 
>receiving immunosuppressive therapy has been reported. Twenty-two of 
>these cases involved recipients of rental transplants.
                                    ^^^^^^

I assume you meant "renal", but it still makes me wonder what would
happen if you missed a few payments.  Ouch.

ABD
Newsgroups: sci.med.aids
From: dyer@spdcc.com (Steve Dyer)
Subject: Re: AZT Inhibits T4 Cell Proliferation
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6275
Organization: S.P. Dyer Computer Consulting, Cambridge MA
Date: Mon, 5 Oct 1992 05:38:22 GMT

In article <1992Oct5.014725.26189@cs.ucla.edu> bigoldberg@igc.apc.org (Billi Goldberg) writes:
>Psoriasis, a skin disease, caused by overproliferation of epidermal 
>cells has been shown to be controlled in AZT users. It appears that at 
>least 800 mg of AZT per day is required to control psoriasis. When AZT 
>is discontinued, the psoriasis returns. Since this overproliferation is 
>probably orchestrated by an immune system response, it seems likely that 
>the inability of helper T cells to proliferate would allevate this 
>condition.

Interestingly, one of the treatments for psoriasis used to be the tri-acetyl
derivative of the nucleoside drug azauridine, azaribine.  It was withdrawn
from marketing due to an increase in thromboembolic events (i.e., the sudden
development of clots and infarcts; this may or may not have been related to
the drug.

It is interesting to speculate how much if any overlap AZT and azaribine
have in their anti-psoriatic activities, or for that matter, whether AZT
would work in non-HIV-related cases of severe psoriasis.  HIV-related
psoriasis, while not common, seems to have some characteristics which
are not shared by HIV-negative individuals with psoriasis.

-- 
Steve Dyer
dyer@ursa-major.spdcc.com aka {ima,harvard,rayssd,linus,m2c}!spdcc!dyer
Newsgroups: sci.med.aids
From: squirrel@cco.caltech.edu (Pat White)
Subject: CDC report of HIV+ population
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6264
Organization: California Institute of Technology, Pasadena
Date: 2 Oct 1992 02:04:45 GMT

There is a question that has bugged me for over a year now.  In 1986, the
CDC estimated that 1,000,000 Americans were infected with HIV.  Now, six
years and about 200,000 deaths later, they still report that 1,000,000
Americans are infected.  Of course, if the same number that get infected
also die each year, then the absolute number will remain constant; however,
they also say that the rate of infection is increasing, which should increase
the absolute number of infected people, especially with the advent of AZT
and other helpful drugs that prolong the lives  of PWA's.

I suspect that they simply don't know, and one million is a nice round
number to quote.  Does anyone know the yardsticks the CDC uses to estimate
HIV infection?

Thanks,

Pat White  (squirrel@cco.caltech.edu)

Newsgroups: sci.med.aids
From: "J. M. Blevins" <AP16%SMUVM1.BITNET@VM.USC.EDU>
Subject:      black hairy leucoplakia(sp?)
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6255
Organization: unspecified
Date:         Wed, 30 Sep 92 13:30:50 CST

any information concerning 'black' would be appreciated.
I have seen the routine leucoplakia, but this is new.
thanks.
J.M. Blevins
Newsgroups: sci.med.aids
From: jfh@netcom.com (Jack Hamilton)
Subject: "Marines go to war over sexy AIDS ad"
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6250
Organization: Netcom - Online Communication Services  (408 241-9760 guest) 
Date: Tue, 29 Sep 92 19:19:21 GMT

[From the San Francisco Examiner, Monday, September 28, 1992.  First three
paragraphs quoted verbatim.]

   The Marine Corps is threatening legal action against the San Francisco 
   AIDS Foundation because a model in one of its sexy ads has a Marine 
   Corp emblem tattooed on his arm, whch is wrap lovingly around another 
   man.

   That is not such an unusual sight in San Francisco.  But is is unusual
   in the Marine Corps, where homosexuality is grounds for immediate 
   discharge.

   "The use of the emblem in your advertisement could create the inference
   that the Marine Corps is somehow partially responsible for the spread
   of AIDS in the San Francisco area," wrote Maj. K. H. Winters, 
   assistant staff judge advocate for research and civil law in Washington,
   D.C., in a July letter to the foundation."

The letter goes on to say that use of the emblem could be taken to mean
that the Marine Corps approves homosexuality, and threatens to sic the 
Attorney General on the SFAF if they don't cease and desist. 

Foundation executive Pat Christen said that they intend to continue using
the ad.  The Marine Corps says that the emblem is copyrighted, and can't be
used in an advertisement without permission.  The legal question is,
apparently, if it's legal for someone to have the tattoo put on his arm
(freedom of expression), can a picture of that arm be used in a photo? 

[I think that the Marine Corps probably *is* partly responsible for the
spead of AIDS in the Bay Area; certainly they're trying to prevent a type
of AIDS education which has been shown to be effective.]

-- 

-----------------------------------------------------------------------
Jack Hamilton   jfh@netcom.com   P. O. Box 281107   SF, CA   94128-1107
Newsgroups: sci.med.aids
From: mmurrain@HAMP.HAMPSHIRE.EDU
Subject: Re: (6251)      Re: (6246) Re: (6236) women and aids
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6253
Organization: unspecified
Date: Wed, 30 Sep 1992 10:38:32 -0500

Folks have asked me about my "complete, current list" of references on
women and AIDS. I would love to share it with folks, except that it is a
"complete, current *file*" :) and is in the beginning process of being put
on a bibliographic database. Thus, alas, will not be available in a list
form for a while. However, when it is, I will be more than happy to send it
to anyone who would like it. If it's not really long I'll post it.
Otherwise, I'll post that I have it, and will send it to interested
parties.
------------------------------------------------------------------
                       Michelle Murrain
  School of Natural Science,Hampshire College Amherst, MA 01002

                   Voice:(413) 549-4600 x688
               email: mmurrain@hamp.hampshire.edu
 Feminism in/and science and technology: fist@hamp.hampshire.edu

------------------------------------------------------------------

Newsgroups: sci.med.aids
From: holzman@mcclb0.med.nyu.edu
Subject: Re: Statistical help needed...
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6265
Organization: NYU Medical Center, New York, NY 10016, USA
Date: 2 Oct 92 08:16:03 EST

In article <1992Oct1.223808.28116@cs.ucla.edu>, tedr@athena.cs.uga.edu (Ted Kalivoda) writes:
> If someone could please assist me with a few numbers.  
> 
> If it is true that roughly 5 out of every 1,000 college students is infected
> with HIV, how could one even begin to calculate the risk of infection.....

You can't unless you are willing to assume students mate randomly.  Data
on risks of sexual encounters are only approximate and probably not good
within a single order of magnitude.  Studies with steady partners of 
infected persons show a wide range of risks.

> Another question:  roughly 40,000 new HIV infection per
> year/350,000,000 (pop of US) = .0000114 number of infection per/population.
> 
> How could one use this figure to say anything worth while?
> 

This is a more useful figure.  The incidence of 1.14 per 100,000 persons
could be compared with the incidence of other diseases and can be trended
over time.  It can be modelled and used to forcast.   
The same caveats about precision apply to estimates of the incidence of 
other diseases. 
Newsgroups: sci.med.aids
From: Billi Goldberg <bigoldberg@igc.apc.org>
Subject: Re: AZT Inhibits T4 Cell Proliferation
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6281
Organization: unspecified
Date: Mon, 5 Oct 92 20:44:14 PDT

I understated the amount of AZT required to clear psoriasas. Further
research shows that 200 mg every fours hours is required or 1200 mg
per day.

I have hear rumors that AZT is being tried in HIV- individuals for
clearance of chronic psoriasis.

Have you heard of using itraconazole for eosinophillic folliculitis
as a primary treatment. A big-name AIDS doctors has stated in a letter
to me that that is treatment of choice. I have checked with Jenssen 
Research Foundation in New Jersey, and they said that itraconazole
was approved in September of this year for hisoplasmosis and blastomycosis.
Dr. Berger at SFGH and UCSF uses topical astemizole as primary treatment.
Jenssen said that itraconazole is only supplied for oral use, and they
have never heard of it being used for eosinophillic folliculitis.

Billi
From: jnynge@ritvax.isc.rit.edu
Newsgroups: sci.med.aids
Subject: women and aids
Date: 28 Sep 92 15:52:21 GMT
Reply-To: jnynge@ritvax.isc.rit.edu
Organization: Rochester Institute of Technology
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6236

Does anyone have any information on some of the early symptoms of
HIV infection that women get?
  Also is there any info on genital warts and HIV infection?
Thanks!
      Jeanne
Newsgroups: sci.med.aids
From: bsmart@bsmart.tti.com (Bob Smart)
Subject: UV and photopheresis
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Reply-To: bsmart@bsmart.tti.com (Bob Smart)
Archive-Number: 6245
Organization: Citicorp+TTI
Date: Mon, 28 Sep 1992 23:42:36 GMT

In view of the recent spate of articles about the perils of UV exposure
and the HIV-activating effect of UV light, I think I'm becoming more
confused, not less.

Am I the only one who remembers an experimental treatment called
"extracorporeal photopheresis?"  It's normally used for treating skin
disorders, and involves having the patient ingest psoralen, then
exposing the patient's blood to UV to activate the psoralen.  There were
a few articles maybe a year back about how this procedure had been tried
on some AIDS patients, and in those few individuals, it seemed to
produce some benefit (elimination of night sweats, wieght gain, etc.),
although all results were extremely preliminary and stated in the most
tentative terms.

So what's the story?  I haven't heard a peep about photopheresis as an
AIDS treatment for ages, and now I'm seeing all these articles about how
UV is a Very Bad Thing for HIV+ patients.  Can somebody resolve this
apparent contradiction?  Is anybody still investigating EP for an AIDS
treatment, or did the whole idea just quietly evaporate?  What happened
to the dozen or so people who were in the original EP-for-HIV experiments?

---------

A fanatic is someone who does what he knows that God would do if God knew the
facts of the case.

Some mailers apparently munge my address; you might have to use
bsmart@bsmart.tti.com -- or if that fails, fall back to
72027.3210@compuserve.com.  Ain't UNIX grand?
Newsgroups: sci.med.aids
From: jbone@splat.dell.com (Jeff Bone)
Subject: ELISA and time-to-antibody-response
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6258
Organization: Dell Computer Co
Date: Wed, 30 Sep 1992 20:44:23 GMT

Quick question...  in my "quest for understanding" I've heard numerous
conflicting statements from various public health agencies.  One of the
ones which most concerns me is the stated interval for antibody expression
and time to reliable ELISA.  

CDC etc. say 12 weeks, the companies that make the test say 6-8 weeks,
and various local agencies say 4-6 mos.  Can anybody cough up some stats
on accuracy of ELISA at various intervals post-exposure?

This oughta be a FAQ question, but... we don't have a FAQ for this group.
--> this is a hint <--  ;) ;)

Thanks in advance...

jb

--
-- Jeff Bone ------------------------------------------------------------
        NT...  Just say N0T.   Skate UN*X!   Standard disclaimer. 
------------------------------------------------------- jbone@dell.com --
                                                                       --
Newsgroups: sci.med.aids
From: bigoldberg@igc.apc.org (Billi Goldberg)
Newsgroups: sci.med.aids
Subject: Re: UVR Activism
Date: 28 Sep 92 04:37:08 GMT
Organization: unspecified
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6234

In post of Sep 26, 1992 at 9:33 PM, Jack Hamilton writes:

>Do you have any reason to think that Dr. Conant is treating HIV+ 
>patients with UV, or recommending self-treatment to them?  If not, I 
>don't see that you have any grounds for complaint about him, given that 
>he seems aware (from what you say later) that there might be a problem.  

Yes, we know that he is using PUVA and recommending UVR for psoriasis 
and other skin problems.

This has been going on for years. 

This complaint is not frivolous.

Billi
From: jfh@netcom.com (Jack Hamilton)
Newsgroups: sci.med.aids
Subject: Re: UVR Activism
Date: 27 Sep 92 04:33:26 GMT
Organization: Netcom - Online Communication Services (408 241-9760 guest)
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6230

In article <1992Sep26.165013.10251@cs.ucla.edu> Billi Goldberg 
<bigoldberg@igc.apc.org> writes:
>
>It has come to my attention that Dr. Marcus A. Conant, a dermatologist, 
>who has a practice in San Francisco, is using a treatment for psoriasis 
>that is extremely dangerous to HIV infected individuals. This treatment 
>is known as PUVA or psoralen used with ultraviolet radiation A (315 to 
>400 nanometers wave length). Along with this treatment, Dr. Conant is 
>recommending that his patients with this problem expose themselves to 
>sunlight to help clear up dermatitis.

Do you have any reason to think that Dr. Conant is treating HIV+ patients
with UV, or recommending self-treatment to them?  If not, I don't see that
you have any grounds for complaint about him, given that he seems aware
(from what you say later) that there might be a problem.  

-- 

-----------------------------------------------------------------------
Jack Hamilton   jfh@netcom.com   P. O. Box 281107   SF, CA   94128-1107
From: "Robert S. Walker" <RWALKER%TRINITY.BITNET@VM.USC.EDU>
Subject:      Re: (6246) Re: (6236) women and aids
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 6251
Organization: unspecified
Date:         Tue, 29 Sep 92 23:38:59 CDT

Michelle,  You mention that you have a fairly complete, and current, list of ma
terials relating to women and AIDS.  Would you be willing to share the bibliogr
aphy with the network generally, or me specifically?  The only publication I ha
ve seen recently that attempts broad coverage is a bulletin on Women and AIDS p
ut out either by Project Inform or Gay Mens Health Crisis.  The materials seem
rather scattered.  I would really appreciate seeing your list, and I am sure ot
hers would as well.

+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+
ROBERT S. WALKER  PH.D.             PHONE:  (512)733-8929, 224-9172
EMERITUS PROFESSOR                  INTERNET: RWALKER@TRINITY.EDU
TRINITY UNIVERSITY, POLSCIDEPT      BITNET: RWALKER@TRINITY.BITNET
715 STADIUM DRIVE                   OFFICE: 128 MAIN PLAZA, NO.310
SAN ANTONIO TX  78212                       SAN ANTONIO, TX, 78205
Newsgroups: sci.med.aids